BioArctic AB Registered b Aktie [WKN DE: A2H5GS / ISIN: SE0010323311]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BioArctic AB Registered Shs -B-

14.03.19		BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease (PR Newswire)
14.03.19		BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease (PR Newswire)
14.02.19		BioArctic - Full Year Report January - December 2018 (PR Newswire)
14.02.19		BioArctic - Full Year Report January - December 2018 (PR Newswire)
13.02.19		BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2 (PR Newswire)
13.02.19		BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2 (PR Newswire)
11.02.19		BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805 (PR Newswire)
11.02.19		BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805 (PR Newswire)
04.02.19		BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease (PR Newswire)
04.02.19		BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease (PR Newswire)
14.12.18		BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance (PR Newswire)
14.12.18		BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance (PR Newswire)
12.11.18		BioArctic is Awarded Grant From EU's Horizon 2020 for Participation in Research Consortium for Better Diagnostic Tools and Biomarkers for Parkinson's (PR Newswire)
08.11.18		Interim Report January - September 2018 (PR Newswire)
08.11.18		Interim Report January - September 2018 (PR Newswire)
02.11.18		BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease (PR Newswire)
02.11.18		BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease (PR Newswire)
25.10.18		BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference (PR Newswire)
25.10.18		BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference (PR Newswire)
03.10.18		BioArctic Receives European Patent Protection for a Medical Device for Treatment of Patients with Complete Spinal Cord Injury (PR Newswire)
13.09.18		BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease (PR Newswire)
13.09.18		BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease (PR Newswire)
03.09.18		BioArctic Expands the Research Collaboration With Uppsala University Concerning Antibody-based Diagnostic Imaging of the Brain in Alzheimer Patients (PR Newswire)
03.09.18		BioArctic Expands the Research Collaboration With Uppsala University Concerning Antibody-based Diagnostic Imaging of the Brain in Alzheimer Patients (PR Newswire)
07.08.18		BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai (PR Newswire)
07.08.18		BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai (PR Newswire)
25.07.18		BioArctic Announces Detailed Results of the BAN2401 Phase 2b Study in Early Alzheimer's Disease Presented at AAIC 2018 (PR Newswire)
25.07.18		BioArctic Announces Detailed Results of the BAN2401 Phase 2b Study in Early Alzheimer's Disease Presented at AAIC 2018 (PR Newswire)
18.07.18		BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer's Disease Will be Webcast Live From AAIC 2018 by Eisai (PR Newswire)
18.07.18		BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer's Disease Will be Webcast Live From AAIC 2018 by Eisai (PR Newswire)
10.07.18		BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
10.07.18		BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
10.07.18		BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018 (PR Newswire)
10.07.18		BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018 (PR Newswire)
06.07.18		BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease (PR Newswire)
06.07.18		BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease (PR Newswire)
16.05.18		BioArctic Receives This Year's SwedenBIO Award (PR Newswire)
16.05.18		BioArctic Receives This Year's SwedenBIO Award (PR Newswire)
14.05.18		BioArctic Extends the Research Collaboration With Uppsala University Regarding New Antibody Technology (PR Newswire)
14.05.18		BioArctic Extends the Research Collaboration With Uppsala University Regarding New Antibody Technology (PR Newswire)
26.04.18		BioArctic - Interim Report January - March 2018 (PR Newswire)
26.04.18		BioArctic - Interim Report January - March 2018 (PR Newswire)
25.04.18		Inclusion Completed of Patients With Complete Spinal Cord Injury in the First Panel of BioArctic's Ongoing Study (PR Newswire)
25.04.18		Inclusion Completed of Patients With Complete Spinal Cord Injury in the First Panel of BioArctic's Ongoing Study (PR Newswire)
21.03.18		BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
21.03.18		BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
19.03.18		BioArctic Receives Patent Protection in Japan for a Medical Device for Treatment of Patients With Complete Spinal Cord Injury (PR Newswire)
19.03.18		BioArctic Receives Patent Protection in Japan for a Medical Device for Treatment of Patients With Complete Spinal Cord Injury (PR Newswire)
21.02.18		BioArctic Receives Regulatory Approval in Estonia for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
21.02.18		BioArctic Receives Regulatory Approval in Estonia for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 19:13
Kaufwert:	EUR
	Hinzufügen Speichern